Generic Name and Formulations:
Isosulfan blue 10mg/mL; soln for SC inj; preservative-free.
Indications for LYMPHAZURIN:
An adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization of the lymphatic system draining the region of injection.
Give by SC inj. 0.5mL into 3 interdigital spaces of each extremity per study. Max dose 3mL (30mg).
Hypersensitivity to triphenylmethane.
Have emergency equipment available for at least 30–60 minutes after injection. Urine color may be blue for 24hrs post administration. Pregnancy (Cat.C). Nursing mothers.
Do not mix with local anesthetics (eg, lidocaine) in the same syringe; precipitation results.
Local reactions, pruritus; anaphylaxis possible.
Single-dose vial (5mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML